LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Home・Aandelen Lijst・SCYNEXIS Inc

SCYNEXIS Inc

Gesloten

0.77

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.72

Max

0.78

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.7M -8.6M
Verkoop	-1M 334K
Winstmarge	-2,572.156
Werknemers	28
EBITDA	9.4M -186K

Marktinformatie
By TradingEconomics
Marktkapitalisatie	4.7M 31M
Vorige openingsprijs	0.77
Vorige sluitingsprijs	0.77

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

0.9307 / 0.9907 Steun & Weerstand

SCYNEXIS Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 mrt 2026, 19:32 UTC

Acquisities, Fusies, Overnames

Diana Shipping Increases Offer to Acquire Genco -- Update

6 mrt 2026, 17:44 UTC

Acquisities, Fusies, Overnames

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

6 mrt 2026, 22:26 UTC

Belangrijke Nieuwsgebeurtenissen

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6 mrt 2026, 22:07 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6 mrt 2026, 22:03 UTC

Marktinformatie

Global Equities Roundup: Market Talk

6 mrt 2026, 22:03 UTC

Marktinformatie

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6 mrt 2026, 21:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Financial Services Roundup: Market Talk

6 mrt 2026, 21:37 UTC

Winsten

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6 mrt 2026, 21:25 UTC

Belangrijke Nieuwsgebeurtenissen

How The Iran War Impacts Ukraine. -- Barrons.com

6 mrt 2026, 21:17 UTC

Winsten

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6 mrt 2026, 20:50 UTC

Winsten

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6 mrt 2026, 20:46 UTC

Winsten

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6 mrt 2026, 20:31 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6 mrt 2026, 20:18 UTC

Marktinformatie

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6 mrt 2026, 20:12 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6 mrt 2026, 19:10 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6 mrt 2026, 18:54 UTC

Marktinformatie

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6 mrt 2026, 18:44 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6 mrt 2026, 18:08 UTC

Winsten

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mrt 2026, 18:04 UTC

Winsten

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mrt 2026, 18:04 UTC

Winsten

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mrt 2026, 17:49 UTC

Marktinformatie

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6 mrt 2026, 17:46 UTC

Belangrijke Nieuwsgebeurtenissen

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6 mrt 2026, 17:40 UTC

Marktinformatie

Winsten

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6 mrt 2026, 17:40 UTC

Winsten

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mrt 2026, 17:32 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6 mrt 2026, 17:28 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6 mrt 2026, 17:20 UTC

Marktinformatie

Winsten

Auto & Transport Roundup: Market Talk

6 mrt 2026, 17:20 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

6 mrt 2026, 17:20 UTC

Acquisities, Fusies, Overnames

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Peer Vergelijking

Prijswijziging

SCYNEXIS Inc Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan SCYNEXIS Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.9307 / 0.9907Steun & Weerstand

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.